Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28073
Full metadata record
DC FieldValueLanguage
dc.contributor.authorArulananda, Surein-
dc.contributor.authorLee, Erinna F-
dc.contributor.authorFairlie, Walter Douglas-
dc.contributor.authorJohn, Thomas-
dc.date2020-12-10-
dc.date.accessioned2021-11-22T05:11:16Z-
dc.date.available2021-11-22T05:11:16Z-
dc.date.issued2021-04-
dc.identifier.citationExpert Review of Anticancer Therapy 2021; 21(4): 413-424en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/28073-
dc.description.abstractIntroduction: With limited recent therapeutic changes, malignant pleural mesothelioma (MPM) is associated with poor survival and death within 12 months, making it one of the most lethal malignancies. Due to unregulated asbestos use in developing countries and home renovation exposures, cases of MPM are likely to present for decades. As MPM is largely driven by dysregulation of tumor suppressor genes, researchers have examined other mechanisms of subverting tumor proliferation and spread. Over-expression of pro-survival BCL-2 family proteins impairs cells from undergoing apoptosis, and BH3-mimetics  targeting them are a novel treatment option across various cancers, though have not been widely investigated in MPM.Areas covered: This review provides an overview of MPM and its current treatment landscape. It summarizes the role of BCL-2 family proteins in tumorigenesis and the therapeutic potential of BH3-mimetics . Finally, it discusses the role of BCL-2 proteins in MPM and the pre-clinical rationale for investigating BH3-mimetics as a therapeutic strategy.Expert opinion: As a disease without readily actionable oncogene driver mutations and with modest benefit from immune checkpoint inhibition, novel therapeutic options are urgently needed for MPM. Hence, BH3-mimetics provide a promising treatment option, with evidence supporting dependence on pro-survival BCL-2 proteins for MPM cell survival.en
dc.language.isoeng
dc.subjectApoptosisen
dc.subjectBCL-2 family proteinsen
dc.subjectBH3-mimeticsen
dc.subjectcell deathen
dc.subjectmalignant pleural mesotheliomaen
dc.titleThe role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma.en
dc.typeJournal Articleen
dc.identifier.journaltitleExpert Review of Anticancer Therapyen
dc.identifier.affiliationDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Heidelberg, Australiaen
dc.identifier.affiliationDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Victoria, Australiaen
dc.identifier.affiliationMedical Oncologyen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.doi10.1080/14737140.2021.1856660en
dc.type.contentTexten
dc.identifier.pubmedid33238762
local.name.researcherFairlie, Walter Douglas
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.